On September 8, 2020 Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, reported Helen Sabzevari, PhD, President and CEO of Precigen, will present at the virtual H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020, at 10:30 AM ET (Press release, Precigen, SEP 8, 2020, https://www.prnewswire.com/news-releases/precigen-to-present-at-hc-wainwright-22nd-annual-global-investment-conference-301125199.html [SID1234564791]). Participants may access the live webcast of the virtual event through Precigen’s website in the Press & Events section at View Source

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!